Oxford BioMedica plc Interim Results for the Six Months Ended 30 June 2011

30 August 2011


Click here to download the full 2011 interim results statement.
Click here to download the 2011 interim results slide deck.

Oxford, UK – 31 August 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today announces its unaudited interim results for the six months ended 30 June 2011.  Year to date highlights include:

LentiVector ® platform
ProSavin®: Parkinson’s disease

  • Positive six-month data from third patient cohort of on-going Phase I/II trial presented at ASGCT 14th Annual Meeting demonstrating 43% average motor function improvement with a 2x dose
  • Improvements across patient diary measures further underline potential for ProSavin®to address the motor symptoms of Parkinson’s disease

Ocular gene therapies: partnered with Sanofi

  • RetinoStat® Phase I study initiated for treatment of “wet” age-related macular degeneration
  • StarGen™ Phase I/IIa study initiated in the US for treatment of Stargardt disease
  • US RAC approval received for UshStat® Phase I/IIa study


  • Acquisition of Oxford manufacturing facility for £1.9 million completed in February 2011, with re-commissioning process on-track

5T4 tumour antigen platform
TroVax® (MVA-5T4): therapeutic cancer vaccine

  • Further TRIST Phase III analyses published in Cancer Immunology, Immunotherapy identifying specific immune response surrogate algorithm
  • Collaborators at Cardiff University and Velindre Cancer Centre, Wales received MHRA and GTAC approval for Phase II study in mesothelioma

Targeted antibody therapy: for cancer

  • Collaboration with Pfizer broadened to include in vitro diagnostic use of 5T4 antibodies
  • New research collaboration with ImaginAb, Inc. to engineer an in vivo diagnostic imaging agent


  • Fundraising of £20.0 million before expenses, completed on 10 January 2011
  • Revenue of £5.0 million (H1 2010 £5.3 million)
  • Research & Development costs of £11.8 million, pre-exceptional £8.7 million (H1 2010 £8.0 million)
  • Net loss of £8.1 million, pre-exceptional £5.0 million (H1 2010 £2.9 million)
  • Net cash burn2 of £10.7 million (H1 2010: £9.4 million)
  • Net cash3 of £20.2 million (H1 2010: £16.3 million)
  •  Financial resources sufficient to fund operations into Q1 2013

1 Unaudited results
2 Net cash generated by/used in operating activities plus sales and purchases of non-current assets
3 Cash, cash equivalents and available for sale investments


  • Collaborators at Cardiff University received MHRA approval for TroVax® Phase II study in colorectal cancer in July 2011
  • StarGen™ CTA approval received in July 2011 for second clinical site in France
  • Positive interim review of fourth ProSavin® patient cohort by DMC  in August 2011 with favourable safety profile at the highest (5x) dose

John Dawson, Chief Executive Officer at Oxford BioMedica, said: “We have made good progress across our core technology platforms during the period. In particular, the ProSavin® Phase I/II data set is very promising and we have broadened our clinical development pipeline from two to four programmes with lead ocular candidates RetinoStat® and StarGen™, partnered with Sanofi, entering Phase I/II development.  With tight fiscal controls in place we have sufficient financial resources to deliver our clinical results and reach our milestone objectives throughout 2012.  We remain committed to building a successful biopharmaceutical company founded on the development and commercialisation of novel gene-based medicines.”